

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **PROGRESS IN CLINICAL TRIAL OF THE GROUP'S PRODUCT UBT251 INJECTION**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors of the Company is pleased to announce that The United Bio-Technology (Hengqing) Co., Ltd., a wholly-owned subsidiary of the Company, has successfully completed Phase Ia clinical trial of UBT251 Injection, a Class 1 innovative drug in healthy subjects in China. Adopting a randomized, double-blind, placebo-controlled, and dose-escalation trial design, this trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of UBT251 in healthy subjects.

The results of this trial showed that all dose arms were safe and well tolerated after a single administration, with no withdrawal of subjects and no serious adverse events. Common side effects were mild to moderate loss of appetite and gastrointestinal-related adverse events. In the dose range of 1.0~4.5mg, the proportion of increase in UBT251 exposure was consistent with the proportion of increase in dose, demonstrating linear pharmacokinetic characteristics, and the mean half-life of each dose arm was 137~170h, which supported one administration by injection weekly. In the dose range of 1.0~4.5mg, the subjects showed a significant decrease in body weight from the baseline, with the mean values of the maximum decrease (E<sub>max</sub>) ranging from -3.19kg to -4.80kg, which was significantly better than that of the placebo arm.

#### **ABOUT UBT251 INJECTION**

UBT251 is a long-acting triple agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulintropic polypeptide)/GCG (glucagon). At present, the Company is the first enterprise in China and the second enterprise in the world to be approved for the clinical trials of a long-acting triple agonist of GLP-1/GIP/GCG prepared by chemical synthetic polypeptide.

The Company will rapidly promote subsequent clinical trials of UBT251 Injection. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 12 August 2024

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.